Description of Research Expertise

I am currently a principal investigator in the Phase 1 clinical trial program at Penn, and also for ECOG-affiliated trials in the Penn GI oncology clinical research program, with my clinical focus being colorectal and anal cancers. I am/was the principal investigator for 2 trials at Penn:

1. EA2165: A Randomized Phase II Study of Nivolumab After Combined Modality Therapy (CMT) in High Risk Anal Cancer -- closed nationally, but data collection is still in progress; and,
2. CA020-002 (BMS): Phase 1/2a First-In-Human Study of BMS-986207 Monoclonal Antibody Alone and in Combination with Nivolumab in Advanced Solid Tumors -- in the process of closing at Penn.

I am also the Medical Monitor for Medical Monitor for UPCC trial 05519; and the Clinical Trial Medical Director for UPenn: Observational Study of a Combined Infusion System to Deliver Chemotherapy Regionally to the Liver, intended to produce a new IND for the FDA combining the Medtronics hepatic artery infusion pump with the Codman hepatic artery infusion catheter.

Description of Clinical Expertise

I am a gastrointestinal oncologist with expertise in all subtypes of GI malignancies but with special expertise with national recognition in colorectal, anal, small intestine, appendiceal, liver metastases (HAI chemotherapy for mCRC), and peritoneal mucinous malignancies. I serve as the Penn representative on NCCN guidelines committees for colon, rectal, anal, small intestine and appendix cancers; the Peritoneal Surface Malignancies Consortium; and the Hepatic Artery Infusion Research Consortium Network (HRCN)